Reporter @statnews.com covering drugs and the biopharma industry | signal: elaineywchen.70https://bsky.app/profile/elaineywchen.bsky.socialhttps://bsky.app/profile/elaineywchen.bsky.social/post/3lukuhyq6us27Latest: A race to develop a new class of narcolepsy drugs could not only transform treatment for patients with the rare sleep disorder, but also many people with common health conditions like Alzheimer's and depression who struggle to stay awake https://www.statnews.com/2025/07/22/narcolepsy-treatment-orexin-trials-future-of-wakefulness-drugs/22 Jul 2025 15:54 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3lukuhyq6us27https://bsky.app/profile/elaineywchen.bsky.social/post/3ls75fgkqtk2gFrom #ADA25: Full results suggest Novo's CagriSema is comparable to Lilly’s Zepbound on safety and efficacy Weight loss looks to be plateauing at the end of late-stage studies, raising Qs around how much more weight patients can lose on the drug https://www.statnews.com/2025/06/22/novo-nordisk-cagrisema-weight-loss-drug-comparison-eli-lilly-zepbound-investors-disappointed/22 Jun 2025 13:11 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3ls75fgkqtk2ghttps://bsky.app/profile/elaineywchen.bsky.social/post/3ls3abpeysc2lLatest from #ADA25: Novo's injectable amycretin showed substantial weight loss in an early study, but similar efficacy across different doses and high rates of side effects raise questions about which dose Novo will pursue going forward https://www.statnews.com/2025/06/20/novo-nordisk-weight-loss-drug-amylin-hormone-injection-effective-but-side-effects-an-issue/20 Jun 2025 23:52 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3ls3abpeysc2lhttps://bsky.app/profile/elaineywchen.bsky.social/post/3lqupmpa4rs2vLATEST: A conservative culture cost Novo Nordisk its lead in the obesity drug race, former employees told me It wanted to tread carefully as the first mover in the space, and its belief in Ozempic/Wegovy blinded it to other candidates, they said https://www.statnews.com/2025/06/05/novo-nordisk-weight-loss-drugs-market-dominance-slips-eli-lilly-gains-here-is-why/05 Jun 2025 16:13 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3lqupmpa4rs2vhttps://bsky.app/profile/elaineywchen.bsky.social/post/3lnxeko4r3s27The explosion of compounded GLP-1 offerings is ending, and many patients are left with no good options. Telehealth companies and compounders are pursuing workarounds that may be riskier. At the same time, patients still can't afford the branded drugs. w/ @katiepalmer.bsky.social https://www.statnews.com/2025/04/29/compounded-glp-1-drugs-patients-seek-semaglutide-alternatives-wegovy-zepbound-mounjaro/29 Apr 2025 13:18 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3lnxeko4r3s27https://bsky.app/profile/elaineywchen.bsky.social/post/3llrwx6xh4s2cRFK Jr. vowed to promote “radical transparency” at HHS. But today the dpt made major cuts to teams across its agencies that handle communications, media relations, and FOIA requests - w/ @lizzylawrence.bsky.social, @isabellacueto.bsky.social https://www.statnews.com/2025/04/01/hhs-rfk-job-cuts-communications-foia-operations/01 Apr 2025 22:40 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3llrwx6xh4s2chttps://bsky.app/profile/elaineywchen.bsky.social/post/3ljalfb2cgk2sPfizer yesterday revised its DEI webpage to emphasize the importance of "merit," joining other companies seeking to align with the Trump administration @jaspar.bsky.social and I laid out all the deletions and insertions in our story https://www.statnews.com/2025/02/27/pfizer-dei-diversity-equity-inclusion-webpage/28 Feb 2025 14:08 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3ljalfb2cgk2shttps://bsky.app/profile/elaineywchen.bsky.social/post/3limhejjsyk2vNEW: Patients in trials of Lilly's next-gen obesity drug tell me they think they're losing too much weight. One started skipping doses, another is making himself eat caloric foods. This is part of what some see as a risky race for more weight loss https://www.statnews.com/2025/02/20/too-much-weight-loss-in-obesity-drug-trial-market-pressure-to-outperform-wegovy-zepbound/20 Feb 2025 14:03 +0000at://did:plc:vodigzzcsftos5bkavjoazup/app.bsky.feed.post/3limhejjsyk2v